Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations

Journal of Virology

Volumn 79, Issue 16, 2005, Pages 10627-10637

  Kitrinos, Kathryn M ^a,c   Nelson, Julie A E ^a,d   Resch, Wolfgang ^a,b,e   Swanstrom, Ronald ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CONTROLLED STUDY; ENVELOPE GENE; GENETIC BOTTLENECK; GENETIC HETEROGENEITY; GENETIC RECOMBINATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PRO GENE; PROTEINASE INHIBITION; VIRUS GENE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GENES, ENV; HETERODUPLEX ANALYSIS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RECOMBINATION, GENETIC; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 23244449323     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.16.10627-10637.2005     Document Type: Article

References (43)

1. Cameron, D. W., M. Healh-Chiozzi, S. Danner, C. Cohen, S. Kravcik, C. Maurath, E. Sun, D. Henry, R. Rode, A. Potthoff, and J. Leonard. 1998. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351:543-549.
2. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
3. Deeks, S. G., J. D. Barbour, J. N. Martin, M. S. Swanson, and R. M. Grant. 2000. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J. Infect. Dis. 181:946-953.
4. Deeks, S. G., F. M. Hecht, M. Swanson, T. Elbeik, R. Loftus, P. T. Cohen, and R. M. Grant. 1999. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13:F35-F43.
5. Deeks, S. G, N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179:1375-1381.
6. Delwart, E. L., and C. J. Gordon. 1997. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 12:348-354.
7. Delwart, E. L., H. Pan, A. Neumann, and M. Markowitz. 1998. Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J. Virol. 72:2416-2421.
8. Delwart, E. L., H. Pan, H. W. Sheppard, D. Wolpert, A. U. Neumann, B. Korber, and J. I. Mullins. 1997. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J. Virol. 71:7498-7508.
9. Dykes, C., P. Mootsikapun, A. Dexter, L. Berries, M. Chiulli, R. C. Reichman, and L. M. Demeter. 2000. Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors. J. Infect. Dis. 182:316-320.
10. Eastman, P. S., J. Mittler, R. Kelso, C. Gee, E. Boyer, J. Kolberg, M. Urdea, J. M. Leonard, D. W. Norbeck, H. Mo, and M. Markowitz. 1998. Genorypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. 72:5154-5164.
11. Ercoli, L., L. Sarmali, E. Nicastri, G. Giannini, C. Galluzzo, S. Vella, and M. Andreoni. 1997. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 11:1211-1217.
12. Fatkenheuer, G., A. Theisen, J. Rockstroh, T. Grabow, C. Wicke, K. Becker, U. Wieland, H. Prisler, M. Reiser, P. Hegener, C. Franzen, A. Schwenk, and B. Salzberger. 1997. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11:F113-F116.
13. Grabar, S., C. Pradier, E. Le Corfec, R. Lancar, C. Allavena, M. Bentata, P. Berlureau, C. Dupont, P. Fabbro-Peray, I. Poizol-Martin, and D. Costagliola. 2000. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 14:141-149.
14. Groenink, M., A. C. Andeweg, R. A. M. Fouchier, S. Broersen, R. C. van der Jagt, H. Schuitemaker, R. E. Y. de Goede, M. L. Bosch, H. G. Huisman, and M. Tersmette. 1992. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J. Virol. 66:6175-6180.
15. Havlir, D. V., S. Eastman, A. Gamst, and D. D. Richman. 1996. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:7894-7899.
16. Hu, W., V. K. Pathak, and H. M. Temin. 1993. Role of reverse transcriptase in retroviral recombination, p. 251-274. In A. M. Skalka and S. P. Goff (ed.), Reverse transcriptase. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
17. Ibanez, A., B. Clotet, and M. A. Martinez. 2000. Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J. Gen. Virol. 81:85-95.
18. Jung, A., R. Maier, J. Vartanian, G. Bocharov, V. Jung, U. Fischer, E. Meese, S. Wain-Hobson, and A. Meyerhans. 2002. Multiply infected spleen cells in HIV patients. Nature 418:144.
19. Kaufmann, D., G. Pantaleo, P. Sudre, and A. Telenti. 1998. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 351:723-724.
20. Kitrinos, K. M., N. G. Hoffman, J. A. E. Nelson, and R. Swanstrom. 2003. Turnover of env variable regions 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J. Virol. 77:6811-6822.
21. Lederman, M. M. 2001. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 15:S11-S15.
22. Lederman, M. M., and H. Valdez. 2000. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 284:223-228.
23. Leigh Brown, A. J., and A. Cleland. 1996. Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS 10:1067-1073.
24. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
25. Morris, A., M. Marsden, K. Halcrow, E. S. Hughes, R. P. Brettle, J. E. Bell, and P. Simmonds. 1999. Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. J. Virol. 73:8720-8731.
26. Nelson, J. A. E., F. Baribaud, T. Edwards, and R. Swanstrom. 2000. Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J. Virol. 74:8494-8501.
27. Nelson, J. A. E., S. A. Fiscus, and R. Swanstrom. 1997. Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J. Virol. 71:8750-8758.
28. Nijhuis, M., C. A. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
29. Paris, D., B. Ledergerber, R. Weber, J. Jost, M. Flepp, M. Opravil, C. Ruef, and S. Zimmerli. 1999. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res. Hum. Retrovir. 15:1631-1638.
30. Peeters, M. 2000. Recombinant HIV sequences: their role in the global epidemic, p. 39-54. In C. L. Kuiken, F. McCutchan, B. Foley, J. W. Mellors, J. I. Mullins, J. Sodroski, and S. Wolinsky (ed.), Human retroviruses and AIDS 2000. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.Mex.
31. Renaud, M., C. Katlama, A. Mallet, V. Calvez, G. Carcelain, R. Tubiana, M. Jouan, E. Caumes, H. Agut, F. Bricaire, P. Debre, and B. Autran. 1999. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 13:669-676.
32. Resch, W., N. Parkin, E. L. Stuelke, and R. Swanstrom. 2000. A multiple site-specific heteroduplex tracking assay as a new tool for the study of viral population dynamics. Proc. Natl. Acad. Sci. USA 98:176-181.
33. Resch, W., N. Parkin, T. Watkins, J. Harris, and R. Swanstrom. 2005. Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J. Virol. 79:10638-10649.
34. Sanchez-Palomino, S., I. Olivares, E. Yusle, D. D. Richman, and C. Lopez-Galindez. 1996. Random important alterations in HIV-1 viral quasispecies after antiviral treatment. Antivir. Ther. 1:225-236.
35. Shannon, C. E., and W. Weaver. 1949. The mathematical theory of communication. University of Illinois Press, Champaign, Ill.
36. Sheeny, N., U. Desselberger, H. Whitwell, and J. K. Ball. 1996. Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine (AZT) therapy. J. Gen. Virol. 77:1071-1081.
37. Simmonds, P., L. Q. Zhang, F. McOmish, P. Balfe, C. A. Ludlam, and A. J. Leigh Brown. 1991. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J. Virol. 65:6266-6276.
38. Swanstrom, R., and J. Eron. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.
39. Wang, F. X., T. Kimura, K. Nishihara, K. Yoshimura, A. Koito, and S. Matsushita. 2002. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J. Infect. Dis. 185:608-617.
40. Wit, F. W., R. van Leeuwen, G. J. Weverling, S. Jurriaans, K. Nauta, R. Steingrover, J. Schuijtemaker, X. Eyssen, D. Fortuin, M. Weeda, F. de Wolf, P. Reiss, S. A. Danner, and J. M. Lange. 1999. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 179:790-798.
41. Wooley, D. P., R. A. Smith, S. Czajak, and R. C. Desrosiers. 1997. Direct demonstration of retroviral recombination in a rhesus monkey. J. Virol. 71:9650-9653.
42. Zhang, Y.-M., S. C. Dawson, D. Landsman, H. C. Lane, and N. P. Salzman. 1994. Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J. Virol. 68:425-432.
43. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.